Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 676-684

  Belani, Chandra P ^a   Kearns, Christine M ^a   Zuhowski, Eleanor G ^a   Erkmen, Kadir ^a   Hiponia, Deborah ^a   Zacharski, Denise ^a   Engstrom, Christine ^a   Ramanathan, Ramesh K ^a   Capozzoli, Mary Jo ^a   Aisner, Joseph ^a   Egorin, Merrill J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; METASTASIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032978689     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.676     Document Type: Article

References (34)

1. Feld R: Chemotherapy versus best supportive care for unresectable non-small cell lung cancer: Is it really worthwhile? Lung Cancer 9:391-396, 1991
2. Kris MG, Gralla RT, Potanovich LM, et al: Assessment of pretreatment symptoms and improvement after edam + mitomycin + vinblastine (EMV) in patients (pts) with inoperable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 9:229, 1990 (abstr 883)
3. Cormier Y, Bergeron D, LaForge J, et al: Benefit of polychemotherapy in advanced non-small cell bronchogenic carcinoma. Cancer 50:854-849, 1985
4. Ganz PA, Figlin RA, Haskell CM, et al: Supportive care versus supportive care and combination chemotherapy in a metastatic non-small cell lung cancer: Does chemotherapy make a difference? Cancer 63:1271-1278, 1989
5. Williams CJ, Woods R, Levi J, Page J: Chemotherapy for non-small cell lung cancer: A randomized trial of cisplatin/vindesine vs no chemotherapy. Semin Oncol 15:58-61, 1988 (suppl 7)
6. Rapp E, Pater JL, William A, et al: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6:663-641, 1988
7. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993
8. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993
9. Ramanathan RK, Belani CP: Chemotherapy for non-small cell lung cancer: Past, present and future. Semin Oncol 24:1-15, 1997
10. Chang AY, Kim K, Glick J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993
11. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
12. Kearns CM, Gianni L, Egorin MJ: Pharmacokinetics and pharmacodynamics of paclitaxel. Semin Oncol 22:16-23, 1995 (3 suppl 6)
13. Ohtsu T, Sasaki Y, Tamura T, et al: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1:599-606, 1995
14. Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
15. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989
16. Egorin MJ, Van Echo DA, Tipping SJ, et al: Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutane di-carboxylate) platinum in patients with impaired renal function. Cancer Res 44:5432-5438, 1984
17. Egorin MJ, Van Echo DA, Olman EA, et al: Prospective validation of a pharmacologically based dosing schema for the cis-diamminedichloroplatinum (II) analogue diammine cyclobutanedicarboxylatoplatinum. Cancer Res 45:6502-6506, 1985
18. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
19. Erkmen K, Egorin MJ, Reyno LM, et al: Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother Pharmacol 35:254-256, 1995
20. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33:48-52, 1993
21. Glantz MJ, Choy H, Kearns CM, et al: Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 8:1077-1081, 1995
22. D'Argenio DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115-134, 1979
23. Yeh KC, Kwan KC: A comparison of numerical integrating algorithms by trapezoidal. LaGrange and Spline approximation. J Pharmacokinet Biopharm 6:79-98, 1978
24. Rocci ML, Jusko WJ: LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 16:203-216, 1983
25. Wagner JG: Kinetics of pharmacologic response: I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 20:173-201, 1968
26. Gianni L, Kearns CM, Giani A: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol 13:180-190, 1995
27. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860-1870, 1995
28. Vafai D, Israel V, Zaretsky S, et al: Phase I/II trial of combination carboplatin and Taxol in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:352, 1995 (abstr 1067)
29. Schutte W, Bork I, Sucker S: Phase II trial of paclitaxel and carboplatin as firstline treatment in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15:A1208, 1996 (abstr)
30. Huizing MT, Giaccone G, van Wamerdam LJC, et al: Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose sequencing study in patients with non-small cell lung cancer. J Clin Oncol 15:317-329, 1997
31. Johnson DH, Paul DM, Hande KR, et al: Paclitaxel plus carboplatin in advanced non-small cell lung cancer: A phase II trial. J Clin Oncol 14:2054-2060, 1996
32. Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
33. van Warmerdam LJC, Huizing MT, ten Bokkel Huinink WW, et al: Can the serum creatinine level be used to calculate the optimal dosage of carboplatin? Proceedings of the 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Amsterdam, The Netherlands, March 1-4, 1995 (abstr 65)
34. Calvert AH, Boddy A, Bailey NP, et al: Carboplatin in combination with paclitaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 22:91-98, 1995 (suppl 12)